Sumifilam

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Cassava Sciences is reducing its workforce by approximately 33% as part of cost-saving measures following Phase 3 trial results.

A class action lawsuit has been filed against Cassava Sciences, alleging securities fraud related to its Alzheimer's drug candidate, simufilam.

Gilead's lenacapavir demonstrated near-perfect efficacy as a twice-yearly injectable for HIV PrEP in Phase III trials, offering a promising alternative to daily oral treatments.

Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.